Stability of Epitheliotrophic Factors in Autologous Serum Eye Drops from Chronic Stevens-Johnson Syndrome Dry Eye Compared to Non-autoimmune Dry Eye

REFERENCES

• Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev. 2008;7:598–605.
   PubMed Web of Science ®Google Scholar
• Definition and Classification Subcommittee members of the International Dry Eye Work Shop. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75–92.
   PubMedGoogle Scholar
• Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467–1474.
   PubMed Web of Science ®Google Scholar
• Rauz S, Saw VP. Serum eye drops, amniotic membrane and limbal epithelial stem cells− tools in the treatment of ocular surface disease. Cell Tissue Bank. 2010;11:13–27.
   PubMed Web of Science ®Google Scholar
• Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol. 2008;71:47–54.
   PubMed Web of Science ®Google Scholar
• Klenkler B, Sheardown H. Growth factors in the anterior segment: Role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res. 2004;79:677–688.
   PubMed Web of Science ®Google Scholar
• Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: Importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res. 2000;19:113–129.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Kinoshita S, Fujita K, et al. The mechanism of accelerated corneal epithelial healing by human epidermal growth factor. Invest Ophthalmol Vis Sci. 1990;31:1773–1778.
   PubMed Web of Science ®Google Scholar
• Kimura K, Kawano S, Mori T, et al. Quantitative analysis of the effects of extracellular matrix proteins on membrane dynamics associated with corneal epithelial cell motility. Invest Ophthalmol Vis Sci. 2010;51:4492–4499.
   PubMedGoogle Scholar
• Harloff S, Hartwig D, Kasper K, Wedel T, Muller M, Geerling G. [Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis]. Klin Monatsbl Augenheilkd. 2008;225:200–206.
   PubMedGoogle Scholar
• Mieliauskaite D, Venalis P, Dumalakiene I, Venalis A, Distler J. Relationship between serum levels of TGF-beta1 and clinical parameters in patients with rheumatoid arthritis and Sjogren’s syndrome secondary to rheumatoid arthritis. Autoimmunity. 2009;42:356–358.
   PubMed Web of Science ®Google Scholar
• Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford). 2007;46:417–425.
   PubMed Web of Science ®Google Scholar
• Management and Therapy Subcommittee members of the International Dry Eye Work Shop. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:163–178.
   PubMedGoogle Scholar
• De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: Patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007;91:1048–1053.
   PubMed Web of Science ®Google Scholar
• Chan LS, Soong HK, Foster CS, Hammerberg C, Cooper KD. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA. 1991;266:1543–1546.
   PubMed Web of Science ®Google Scholar
• Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology. 1988;95:453–462.
   PubMed Web of Science ®Google Scholar
• Yamada C, King KE, Ness PM. Autologous serum eyedrops: Literature review and implications for transfusion medicine specialists. Transfusion. 2008;48:1245–1255.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: Timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182:8071–8079.
   PubMed Web of Science ®Google Scholar
• Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol. 2009;16:274–279.
   PubMed Web of Science ®Google Scholar
• Bradley JC, Bradley RH, McCartney DL, Mannis MJ. Serum growth factor analysis in dry eye syndrome. Clin Experiment Ophthalmol. 2008;36:717–720.
   PubMed Web of Science ®Google Scholar
• Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol. 2005;243:706–714.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106:1984–1989.
   PubMed Web of Science ®Google Scholar
• Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996;15:605–614.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Fullard RJ, Willcox MD, et al. Fibronectin in the tear film. Invest Ophthalmol Vis Sci. 1996;37:459–467.
   PubMed Web of Science ®Google Scholar
• Kokawa N, Sotozono C, Nishida K, Kinoshita S. High total TGF-beta 2 levels in normal human tears. Curr Eye Res. 1996;15:341–343.
   PubMed Web of Science ®Google Scholar
• Prabhasawat P, Chotikavanich S, Leelaporn A. Sterility of non-preservative eye drops. J Med Assoc Thai. 2005;88(Suppl. 9):S6–10.
   Google Scholar
• Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: Clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85:1188–1197.
   PubMed Web of Science ®Google Scholar
• Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802–806.
   PubMed Web of Science ®Google Scholar
• Lagnado R, King AJ, Donald F, Dua HS. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol. 2004;88:464–465.
   PubMed Web of Science ®Google Scholar
• Bradley JC, Simoni J, Bradley RH, McCartney DL, Brown SM. Time- and temperature-dependent stability of growth factor peptides in human autologous serum eye drops. Cornea. 2009;28:200–205.
   PubMed Web of Science ®Google Scholar